A race for a better understanding of COVID-19 vaccine non-adopters

Zhaohui Su
Jun Wen
Edith Cowan University
Jaffar Abbas
Dean McDonnell
Ali Cheshmehzangi

See next page for additional authors

Follow this and additional works at: https://ro.ecu.edu.au/ecuworkspost2013

Part of the Epidemiology Commons

10.1016/j.bbih.2020.100159
This Other is posted at Research Online.
https://ro.ecu.edu.au/ecuworkspost2013/11223
Authors
Zhaohui Su, Jun Wen, Jaffar Abbas, Dean McDonnell, Ali Cheshmehzangi, Xiaoshan Li, Junaid Ahmad, Sabina Šegalo, Daniel Maestro, and Yuyang Cai
A race for a better understanding of COVID-19 vaccine non-adopters

Zhaohui Su a,∗, Jun Wen b, Jaffar Abbasi c, Dean McDonnell d, Ali Cheshmezhangi e, Xiaoshan Li f, Junaid Ahmad g, Sabina Segalo h, Daniel Maestro i, Yuyang Cai j

a Incoming Postdoctoral Fellow, Center on Smart and Connected Health Technologies, Mays Cancer Center, School of Nursing, UT Health San Antonio, San Antonio, TX, 78229, USA
b School of Business and Law, Edith Cowan University, Perth, WA, 6027, Australia
c Antal College of Economics and Management, and School of Media and Communication, Shanghai Jiao Tong University, 200240, Shanghai, China
d Department of Humanities, Institute of Technology Carlow, Carlow, R93 V960, Ireland
e Head of Department of Architecture and Built Environment, Professor of Architecture and Urban Design, Faculty of Science and Engineering, University of Nottingham
f Ningbo University—Hong Kong Baptist University United International College, China
g Prime Institute of Public Health, Peshawar Medical College, Peshawar, Warsak Road, Peshawar, 25160, Pakistan
h Department of Microbiology, Faculty of Medicine, University of Sarajevo, Sarajevo, 71000, Bosnia and Herzegovina
i Department of Environmental Health, Institute for Public Health of Federation Bosnia and Herzegovina, Sarajevo, 71000, Bosnia and Herzegovina
j China Institute for Urban Governance, Shanghai Jiao Tong University School of Medicine, Shanghai, 200025, China

A R T I C L E   I N F O

Keywords:
COVID-19
Coronavirus
Vaccination
Vaccines
Vaccine hesitancy
Vaccine non-adopters

A B S T R A C T

In this paper, we aim to underscore the need for a more nuanced understanding of vaccine non-adopters. As the availability of vaccines does not translate into their de facto adoption—a phenomenon that may be more pronounced amid “Operation Warp Speed”—it is important for public health professionals to thoroughly understand their “customers” (i.e., end users of COVID-19 vaccines) to ensure satisfactory vaccination rates and to safeguard society at large.

A cure for COVID-19 is urgently needed. As COVID-19 outbreaks of various sizes and the public outcry over social and economic freedom have become the “new normal,” it is clear that physical contact-limiting mechanisms such as lockdowns, self-isolation, and social distancing are not sustainable long-term countermeasures against the spread of the SARS-CoV-2 virus. It has become even clearer that non-pharmaceutical interventions like social distancing are contingency plans; a cure for the ever-spreadind COVID-19 pandemic is expected elsewhere, most probably in pharmaceutical solutions like COVID-19 vaccines. High hopes are being placed on COVID-19 vaccines with the potential to curb the spread of the novel coronavirus and, in turn, prevent societies across the world from facing ongoing COVID-19 incidence and deaths. The plan is simple: develop a vaccine and possibly save the world. With a pronounced need for vaccines to halt the spread of COVID-19, talents and international are bound by the same shared, determined, and fervent desire to see the world vaccinated and return to “normal.”

Time is of the essence. Although the name “Operation Warp Speed” refers specifically to America’s COVID-19 vaccine programs, speed has been the focus of most (Mullard, 2020), if not all, such programs since their inception in a race for the first approved COVID-19 vaccine. Yet in the midst of a global health crisis, few seem to have considered COVID-19 vaccines, which are essentially consumer health products (Su et al., 2019), in the context of the classic supply-demand economic model. Much of the world has been concentrating on developing a vaccine, representing the supply side of the equation. Meanwhile, not enough questions are being asked from the demand side: who are the potential consumers of COVID-19 vaccines? Though many vaccine programs, whether initiated by non-profit or for-profit pharmaceutical companies, are government-sponsored, funding from governmental agencies only
indicates that these agencies are purchasers or direct customers of potential vaccines; they are not the same as end users or fundamental consumers. In other words, although governmental demand for COVID-19 vaccines has been most noticeable, it is individual citizens who will be receiving these vaccines (i.e., end users). This understanding has many implications, one of which centres on the need for a common advertising or marketing practice—consumer analysis.

As the literature indicates, when it comes to end users of consumer health technologies such as vaccines, their attitudes, knowledge, and intentions to adopt a COVID-19 vaccine vary greatly (World Health Organization, 2014). A joint study conducted by the Associated Press and the University of Chicago (AP-NORC) in May 2020 showed that COVID-19 vaccine availability would not translate into vaccine adoption for 51% of Americans surveyed (The Associated Press, 2020). Among these vaccine non-adopters, 31% were hesitant about adopting a COVID-19 vaccine, whereas 1 in 5 said they would refuse the vaccine outright (The Associated Press, 2020). These findings resonate with the results of an early study conducted by a group of French scientists in March 2020, who found that among a representative sample of the French population, 26% indicated they would refuse a COVID-19 vaccine once it becomes available (Roup and A Future v, 2020). Furthermore, despite being particularly vulnerable to COVID-19, non-adoption rates among people of low socioeconomic status are even more alarming: approximately 37% stated they would refuse a COVID-19 vaccine regardless of availability (Roup and A Future v, 2020). As disturbing as they may be, these findings are hardly surprising (The Lancet and Looking beyon, 2018). Research suggests that across infectious disease contexts and vaccine types, vaccine non-adopters (often characterised as expressing “vaccine hesitancy”) are prevalent (World Health Organization, 2014; The Lancet and Looking beyon, 2018; Larson et al., 2007).

Vaccine hesitancy poses a substantial threat to global health and is a top 10 priority of the World Health Organization (WHO) (World Health Organization, 2019a). Per the WHO, this phenomenon refers to “delay in acceptance or refusal of vaccines despite availability of vaccination services” (World Health Organization, 2015). Within the vaccine-related literature, vaccine hesitancy is among the limited terms available that centres on the demand rather than supply side of vaccine adoption. In theory, the term “vaccine hesitancy” should capture only one aspect (i.e., reluctance) of vaccine consumers’ nuanced rationale for being vaccine non-adopters. The crux of this issue is that “vaccine hesitancy” in fact covers myriad distinctive reasons for vaccine non-adoption, ranging from delay to indecision to reluctance to refusal. In other words, the term can be used to represent a considerable proportion of vaccine non-adopters without paying mind to these potential consumers’ distinct traits. Therefore, the effectiveness of this definition is questionable in terms of helping health experts better understand vaccine non-adopters’ unique concerns about COVID-19 vaccines to address these anxieties accordingly.

A more accurate term to refer to people who do not adopt vaccines is “vaccine non-adopters.” Vaccine non-adopters are not one group of individuals but rather encompass many groups who possess distinct reasons for vaccine non-adoption (World Health Organization, 2014). Some vaccine non-adopters may be highly informed about vaccine efficacy and safety, such as the efficacy of established vaccines like the flu vaccine, and decide not to get vaccinated (Su et al., 2019). Other vaccine non-adopters might choose not to get vaccinated because they do not realise they must receive the vaccine to be protected from contracting SARS-CoV-2 (Roup and A Future v, 2020). It is important to note that some non-adoption decisions made by vaccine non-adopters could be based on justified considerations (The Associated Press, 2020), such as individuals who are allergic to egg proteins (Centers for Disease Contr, 2020). Take influenza vaccines for instance. Though some influenza vaccines do not contain egg proteins and the Centers for Disease Control and Prevention in the United States, for instance, no longer recommends that people with egg allergies need to be observed for an allergic reaction for 30 min, people who are allergic to egg proteins still need to be vaccinated in an inpatient or outpatient medical setting (Centers for
to promote COVID-19 vaccine adoption, they first need to obtain a fine-grained understanding of their target audiences or customers. After all, the term “vaccine non-adopters” encompasses a large group of people from diverse backgrounds (Larson et al., 2007), including well-educated individuals without vaccine-related allergies who may still refuse to adopt a COVID-19 vaccine. To ensure that meaningful population-level SARS-CoV-2 immunity can be achieved with the help of safe and effective COVID-19 vaccines, policymakers, health experts, and health communication professionals should, first and foremost, understand the many characteristics of vaccine non-adopters and develop tailored communication strategies and campaign deliverables. Considering the potentially grave health and financial consequences of an unvaccinated majority once COVID-19 vaccines become available, a race for a better understanding of the characteristics of COVID-19 vaccine non-adopters is needed—perhaps as urgently, if not more so, as the race for effective vaccines.

Declaration of competing interest

None.

References